Phoenix Technology Group Granted Its Third Patent on the Phoenix ICON™ Technology

Phoenix issued US patent teaching implementation of hand-held optical coherence tomography (OCT)

 

Pleasanton, CA, USA,  January 25, 2021 – Today, Phoenix Technology Group LLC (Phoenix), a leading provider of advanced ophthalmic imaging solutions, announced today that the third US patent covering the Phoenix ICON technology has been issued. US Patent 10,893,803 issued on January 19, 2021, and teaches the addition of optical coherence tomography (OCT) to the camera hand piece of a Phoenix ICON system.

Phoenix ICON systems enable high-resolution, high-contrast imaging of the retinal, corneal, and external eye structures. The unique, patented ICON imaging technology injects light into the eye in an annular pattern, leaving the center open for unobstructed returned light from the retina. Further, the ICON system perfects the image to be captured at the imaging sensor instead of closer to the entrance pupil, as is typical in these imaging systems. These techniques allow for the generation and capture of very high quality retinal images, as seen in the current Phoenix ICON products.

Optical coherence tomography (OCT) is an imaging technique that uses low-coherence light to capture micrometer-resolution, two- and three-dimensional images from within optical scattering media. When used to image the retina, OCT allows observation of the layers of the retina to identify the presence and progression of ophthalmic pathologies.

The ‘803 patent teaches the addition of OCT imaging to the Phoenix ICON camera hand piece. One embodiment of the invention takes advantage of the unique annular illumination technique to integrate the OCT laser imaging system without interrupting or disturbing the fundus imaging capabilities of the camera. Adding OCT to the Phoenix ICON camera hand piece would introduce both a hand-held implementation of OCT for use with non-ambulatory patients, as well as provide for implementation of image-guided OCT capture by which the operator could view a live fundus image concurrently with viewing and capturing an OCT image. Such an implementation would be similar to the widely acclaimed Phoenix MICRON imaging microscope used by researchers around the world.

“Phoenix is committed to innovating new and valuable technologies that we can commercialize through our hardware, software, and cloud products to help our research and clinical customers see and understand more about the eye in their ongoing fight to save eyesight,” said J. Scott Carr, chairman and CEO of Phoenix. “The ‘803 patent sets the stage for a new generation of ICON technology to be developed over the coming years to bring additional imaging modalities to an already successful clinical product line. I’m proud of the Phoenix team and look forward to commercialization of this and other inventions for the benefit of our customers and their patients.”

 

About Phoenix Technology Group:  Phoenix Technology Group empowers people to see: we empower researchers to see more in their fight to prevent blindness; we empower clinicians to see more in their fight to save sight.  We do that by providing clinicians and researchers around the world with stunning retinal images, coupled with timely and accurate data about the retina and the eye. Founded by Bert Massie, Ph.D., inventor of the first digital camera for pediatric retinal imaging, our company created the Phoenix MICRON™ platform for in-vivo imaging of animals in eye research.  Phoenix MICRON is the standard of excellence for researchers worldwide: ten of the top twelve research institutions employ a Phoenix MICRON solution. In 2017, the company launched to great acclaim the Phoenix ICON™ platform which reinvented wide-field retinal imaging for human clinical applications. Phoenix ICON delivers stunning high-contrast, high-resolution images, with quality you can see and data you can trust. Recognizing that telemedicine is the future of retinopathy of prematurity (ROP) screening, in 2018, Phoenix launched the Phoenix CONNECT™ platform, which today is the most widely adopted telemedicine platform for ROP screening. The CONNECT platform connects the nursing, ophthalmology, and neonatology teams to enable delivery of the best care by facilitating timely expert screening of babies in any NICU. And, the platform implements a proven screening workflow that generates critical photo documentation to enhance treatment determination and reduce risk.

 

Contact: Jen King, Phoenix Technology Group, ph.1.925.485.1100 x 244, jen.king@phoenixtech.com